Christos Hatzis, PhD
Research & Publications
Biography
News
Research Summary
Dr. Hatzis continues to be involved in the design of biomarker validation clinical studies and development of strategies for translating genomic diagnostic assays to clinical practice. His current research interests focus on developing methods to characterize the genetic and molecular heterogeneity of breast cancer subtypes and the implications it might have on response and resistance to treatment. A key area of interest is to develop methodology that integrates genomic level information of individual patients to lead to more focused treatment decisions tailored for the individual tumor.
Speciailized Terms: Personalized medicine; Molecular diagnostics; Cancer heterogeneity; Next generation sequencing; Diagnostic study design
Extensive Research Description
Characterization of molecular and genetic heterogeneity in breast cancer and its association with treatment response or resistance.
Evaluation of high-throughput drug screens for triple negative breast cancer and assocation of sensitivity to genetic background.
Translation of microarray based prognostic tests to next generation platforms.
Coauthors
Research Interests
Breast Neoplasms; Medical Oncology; Genetic Heterogeneity; Molecular Diagnostic Techniques
Selected Publications
- Comprehensive Analysis of Metabolic Isozyme Targets in CancerMarczyk M, Gunasekharan V, Casadevall D, Qing T, Foldi J, Sehgal R, Shan NL, Blenman KRM, O'Meara TA, Umlauf S, Surovtseva YV, Muthusamy V, Rinehart J, Perry RJ, Kibbey R, Hatzis C, Pusztai L. Comprehensive Analysis of Metabolic Isozyme Targets in Cancer. Cancer Research 2022, 82: 1698-1711. PMID: 35247885, PMCID: PMC10883296, DOI: 10.1158/0008-5472.can-21-3983.
- Abstract P2-07-05: Activation of the AKT/mTOR signaling pathway is associated with response to the combination of endocrine therapy and CDK4/6 inhibitor in HR+/HER2- metastatic breast cancerAbu-Khalaf M, Hatzis C, Hodge K, Baldelli E, Sikov W, Mita M, Valdes-Albini F, Dunetz B, Petricoin E, Pierobon M. Abstract P2-07-05: Activation of the AKT/mTOR signaling pathway is associated with response to the combination of endocrine therapy and CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer. Cancer Research 2022, 82: p2-07-05-p2-07-05. DOI: 10.1158/1538-7445.sabcs21-p2-07-05.
- Abstract PO-045: Observational study assessing survival outcomes in advanced melanoma patients with brain metastases treated with immunotherapy with or without radiotherapy: Effect of radiotherapy sequence and modalityOrduno N, Shao X, Garnett-Benson C, Rizzo J, Moss R, Le T, Hatzis C. Abstract PO-045: Observational study assessing survival outcomes in advanced melanoma patients with brain metastases treated with immunotherapy with or without radiotherapy: Effect of radiotherapy sequence and modality. Clinical Cancer Research 2021, 27: po-045-po-045. DOI: 10.1158/1557-3265.radsci21-po-045.
- Abstract PS5-28: Multiomic advanced diagnostics for CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancerAbu-Khalaf M, Hatzis C, Hodge K, Valdes F, Sikov W, Mita M, Denduluri N, Awerkamp K, Murphy R, Zelterman D, Dunetz B, Petricoin E, Pierobon M. Abstract PS5-28: Multiomic advanced diagnostics for CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer. Cancer Research 2021, 81: ps5-28-ps5-28. DOI: 10.1158/1538-7445.sabcs20-ps5-28.
- 733 Integrative molecular profiling of high-grade primary prostate cancer identifies patients with a biomarker profile that favors the combination of standard of care (SOC) therapy with immunotherapyGjini E, Trillo-Tinoco J, Browne A, Powles R, Wang T, Tauras C, Lako A, Ferrer-Luna R, Bleicher Z, Consedine T, Zhou C, Kelemen E, Lewin A, King C, Bhattacharya S, Bell-Temin H, Dongre A, Nelson D, Hatzis C, Macisaac K, Towfic F, Chen B, Bowden M. 733 Integrative molecular profiling of high-grade primary prostate cancer identifies patients with a biomarker profile that favors the combination of standard of care (SOC) therapy with immunotherapy. Journal For ImmunoTherapy Of Cancer 2020, 8: a438-a439. DOI: 10.1136/jitc-2020-sitc2020.0733.
- 496 Immune cell profiling across solid tumor types by mass cytometry reveals tumor enrichment of PD-1+/LAG-3+ CD8 memory T cells that exhibit tumor-reactive yet dysfunctional featuresGarman B, Menard L, Jiang C, Daouti S, Mehta P, Jacques M, Bolisetty M, Hatzis C, Orduno N, Bowden M, David J, David J, David J. 496 Immune cell profiling across solid tumor types by mass cytometry reveals tumor enrichment of PD-1+/LAG-3+ CD8 memory T cells that exhibit tumor-reactive yet dysfunctional features. Journal For ImmunoTherapy Of Cancer 2020, 8: a531-a531. DOI: 10.1136/jitc-2020-sitc2020.0496.
- Abstract 6333: Genomic, transcriptomic, and epigenetic profiling of triple-negative breast cancer cells after Navitoclax treatmentMarczyk M, Gunasekharan V, Zhao J, Qu R, Li X, Patwardhan G, Wali V, Gupta A, Pillai M, Kluger Y, Hatzis C, Pusztai L. Abstract 6333: Genomic, transcriptomic, and epigenetic profiling of triple-negative breast cancer cells after Navitoclax treatment. Cancer Research 2020, 80: 6333-6333. DOI: 10.1158/1538-7445.am2020-6333.
- Abstract A089: Addressing both community and institutional barriers increases accrual of minority patients in breast cancer clinical trialsTrant A, Walz L, Allen W, Verma H, Le M, DeJesus J, Hatzis C, Silber A. Abstract A089: Addressing both community and institutional barriers increases accrual of minority patients in breast cancer clinical trials. Cancer Epidemiology Biomarkers & Prevention 2020, 29: a089-a089. DOI: 10.1158/1538-7755.disp18-a089.
- CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer for treatment selection and response prediction.Abu-Khalaf M, Hatzis C, Hodge K, Valdes F, Sikov W, Mita M, Denduluri N, Awerkamp K, Murphy R, Zelterman D, Dunetz B, Petricoin E, Pierobon M. CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer for treatment selection and response prediction. Journal Of Clinical Oncology 2020, 38: e13029-e13029. DOI: 10.1200/jco.2020.38.15_suppl.e13029.
- Abstract P5-13-02: Neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and an oncotype Dx recurrence score (≤25)Abu-Khalaf M, Aderhold K, Marczyk M, Chung G, Hofstatter E, Sanft T, Silber A, DiGiovanna M, Zelterman D, Puzstai L, Hatzis C. Abstract P5-13-02: Neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and an oncotype Dx recurrence score (≤25). Cancer Research 2020, 80: p5-13-02-p5-13-02. DOI: 10.1158/1538-7445.sabcs19-p5-13-02.
- Breast Cancer Heterogeneity Investigation: Multiple k-Means Clustering ApproachTobiasz J, Hatzis C, Polanska J. Breast Cancer Heterogeneity Investigation: Multiple k-Means Clustering Approach. 2019, 00: 410-414. DOI: 10.1109/bibe.2019.00080.
- A prospective decision-impact study incorporating Breast Cancer Index into extended endocrine therapy decision-makingSanft T, Berkowitz A, Schroeder B, Hatzis C, Schnabel C, Brufsky A, Gustavsen G, Pusztai L, Londen G. A prospective decision-impact study incorporating Breast Cancer Index into extended endocrine therapy decision-making. Breast Cancer Management 2019, 8: bmt22. DOI: 10.2217/bmt-2019-0001.
- Abstract P3-05-01: Age-related methylation signals of breast cancer risk in bloodHofstatter E, Levine M, Hatzis C, Pusztai L. Abstract P3-05-01: Age-related methylation signals of breast cancer risk in blood. Cancer Research 2019, 79: p3-05-01-p3-05-01. DOI: 10.1158/1538-7445.sabcs18-p3-05-01.
- Abstract OT3-02-06: Utilizing multiomic advanced diagnostics to identify CDK4/6 inhibitor response predictors and a post-treatment multiomic signature for patients with ER+/HER2- metastatic breast cancer (SIDEOUT-3)Abu-Khalaf M, Pierobon M, Denduluri N, Valdes-Albini F, Forero-Torres A, Clark A, Yung R, Mita M, Christensen S, Awerkamp K, Dunetz B, Murphy R, Hatzis C, Zelterman D, Liotta L, Petricoin E. Abstract OT3-02-06: Utilizing multiomic advanced diagnostics to identify CDK4/6 inhibitor response predictors and a post-treatment multiomic signature for patients with ER+/HER2- metastatic breast cancer (SIDEOUT-3). Cancer Research 2019, 79: ot3-02-06-ot3-02-06. DOI: 10.1158/1538-7445.sabcs18-ot3-02-06.
- Abstract P2-06-06: Targeting loss of isoenzyme diversity as a novel therapeutic strategy in breast cancerMarczyk M, Gunasekharan V, Wali V, Shi W, Patwardhan G, Qing T, Pusztai L, Hatzis C. Abstract P2-06-06: Targeting loss of isoenzyme diversity as a novel therapeutic strategy in breast cancer. Cancer Research 2019, 79: p2-06-06-p2-06-06. DOI: 10.1158/1538-7445.sabcs18-p2-06-06.
- Abstract P3-10-01: Single-cell profiling identifies hypoxic carcinoma cells as source of an immunosuppressive VEGFA metageneKarn T, Denkert C, Sinn B, Weber K, Nekljudova V, Rody A, Meissner T, Hatzis C, El-Balat A, Becker S, Solbach C, Untch M, Schneeweiss A, von Minckwitz G, Loibl S, Pusztai L, Holtrich U. Abstract P3-10-01: Single-cell profiling identifies hypoxic carcinoma cells as source of an immunosuppressive VEGFA metagene. Cancer Research 2019, 79: p3-10-01-p3-10-01. DOI: 10.1158/1538-7445.sabcs18-p3-10-01.
- Abstract P4-03-01: Pathway level complementarity of germline and somatic events in breast cancerQing T, Marczyk M, Wali V, Gunasekharan V, Patwardhan G, Pusztai L, Hatzis C. Abstract P4-03-01: Pathway level complementarity of germline and somatic events in breast cancer. Cancer Research 2019, 79: p4-03-01-p4-03-01. DOI: 10.1158/1538-7445.sabcs18-p4-03-01.
- Abstract P4-08-20: Pre-analytical effects of FFPE extraction methods on targeted and whole transcriptome sequencing assays for endocrine sensitivity in metastatic breast cancerMarczyk M, Fu C, Lau R, Du L, Trevarton A, Sinn B, Gould R, Symmans W, Hatzis C. Abstract P4-08-20: Pre-analytical effects of FFPE extraction methods on targeted and whole transcriptome sequencing assays for endocrine sensitivity in metastatic breast cancer. Cancer Research 2019, 79: p4-08-20-p4-08-20. DOI: 10.1158/1538-7445.sabcs18-p4-08-20.
- Abstract PD5-10: Immune characterization of matched primary and multiple metastatic samples issued from an institutional autopsy cohortSzekely B, Bareche Y, Van den Eynden G, Salgado R, Buisseret L, Garaud S, Willard-Gallo K, Hatzis C, Szasz M, Kulka J, Larsimont D, Sotiriou C, Pusztai L, Desmedt C. Abstract PD5-10: Immune characterization of matched primary and multiple metastatic samples issued from an institutional autopsy cohort. Cancer Research 2019, 79: pd5-10-pd5-10. DOI: 10.1158/1538-7445.sabcs18-pd5-10.
- Immune profiling of pre- and post-treatment breast cancer tissues from the S0800 randomized neoadjuvant trial of weekly nab-paclitaxel with or without bevacizumab and dose dense doxorubicin and cyclophosphamide.Li X, Warren S, Pelekanou V, Wali V, Cesano A, Liu M, Danaher P, Elliott N, Nahleh Z, Hayes D, Hortobagyi G, Barlow W, Hatzis C, Pusztai L. Immune profiling of pre- and post-treatment breast cancer tissues from the S0800 randomized neoadjuvant trial of weekly nab-paclitaxel with or without bevacizumab and dose dense doxorubicin and cyclophosphamide. Journal Of Clinical Oncology 2018, 36: 578-578. DOI: 10.1200/jco.2018.36.15_suppl.578.
- Abstract PD6-02: Immunological differences between primary and metastatic breast cancerSzekely B, Bossuyt V, Li X, Baine M, Silber A, Sanft T, Hofstatter E, Mougalian S, Baghwagar S, Neumeister V, Pelekanou V, Hatzis C, Pusztai L. Abstract PD6-02: Immunological differences between primary and metastatic breast cancer. Cancer Research 2018, 78: pd6-02-pd6-02. DOI: 10.1158/1538-7445.sabcs17-pd6-02.
- Abstract P1-07-10: Molecular subtypes of triple negative breast cancer have different sensitivity signature to established chemotherapy agentsGyőrffy B, Nagy Á, Santarpia L, Hatzis C. Abstract P1-07-10: Molecular subtypes of triple negative breast cancer have different sensitivity signature to established chemotherapy agents. Cancer Research 2018, 78: p1-07-10-p1-07-10. DOI: 10.1158/1538-7445.sabcs17-p1-07-10.
- Abstract P2-04-02: Comparison of DNA methylation patterns in normal breast tissue from women with and without breast cancerHofstatter E, Zhu Y, Horvath S, Chagpar A, Wali V, Bossuyt V, Storniolo A, Hatzis C, Patwardhan G, Von Wahlde M, Butler M, Epstein L, Stavris K, Sturrock T, Au A, Kwei S, Pusztai L. Abstract P2-04-02: Comparison of DNA methylation patterns in normal breast tissue from women with and without breast cancer. Cancer Research 2018, 78: p2-04-02-p2-04-02. DOI: 10.1158/1538-7445.sabcs17-p2-04-02.
- Abstract P2-09-01: T-cell receptor beta chain variable region (TRBV) expression patterns predict response to combined trastuzumab/lapatinib treatment in the NeoALTTO/BIG-1-06 trialPowles R, Redmond D, Sotiriou C, Loi S, Fumagalli D, Nuciforo P, Harbeck N, de Azambuja E, Sarp S, Di Cosimo S, Huober J, Baselga J, Piccart-Gebhart M, Elemento O, Hatzis C, Pusztai L. Abstract P2-09-01: T-cell receptor beta chain variable region (TRBV) expression patterns predict response to combined trastuzumab/lapatinib treatment in the NeoALTTO/BIG-1-06 trial. Cancer Research 2018, 78: p2-09-01-p2-09-01. DOI: 10.1158/1538-7445.sabcs17-p2-09-01.
- Revisiting inconsistency in large pharmacogenomic studiesSafikhani Z, Smirnov P, Freeman M, El-Hachem N, She A, Rene Q, Goldenberg A, Birkbak N, Hatzis C, Shi L, Beck A, Aerts H, Quackenbush J, Haibe-Kains B. Revisiting inconsistency in large pharmacogenomic studies. F1000Research 2017, 5: 2333. DOI: 10.12688/f1000research.9611.2.
- Abstract 1141: Evaluation of GABRP as a novel therapeutic target in triple negative breast cancerWali V, Patwardhan G, Hatzis C, Pusztai L. Abstract 1141: Evaluation of GABRP as a novel therapeutic target in triple negative breast cancer. Cancer Research 2017, 77: 1141-1141. DOI: 10.1158/1538-7445.am2017-1141.
- Abstract 2073: A systematic investigation of the effect of scheduling of targeted combination therapies on response and dynamics of relapse in triple negative breast cancer cellsPatwardhan G, Wali V, Pusztai L, Hatzis C. Abstract 2073: A systematic investigation of the effect of scheduling of targeted combination therapies on response and dynamics of relapse in triple negative breast cancer cells. Cancer Research 2017, 77: 2073-2073. DOI: 10.1158/1538-7445.am2017-2073.
- Differences in the immune microenvironment and genomic characteristics of TNBC in African American women compared to other races.Szekely B, Safonov A, Karn T, Bhagwagar S, Killelea B, Silber A, Hatzis C, Pusztai L. Differences in the immune microenvironment and genomic characteristics of TNBC in African American women compared to other races. Journal Of Clinical Oncology 2017, 35: e13028-e13028. DOI: 10.1200/jco.2017.35.15_suppl.e13028.
- Long-term survival of de novo stage IV human epidermal growth factor receptor 2 (HER2)-positive breast cancers treated with HER2 targeted therapy.Wong Y, Raghavendra A, Hatzis C, Irizarry J, Vega T, Barcenas C, Chavez-Mac Gregor M, Valero V, Tripathy D, Pusztai L, Murthy R. Long-term survival of de novo stage IV human epidermal growth factor receptor 2 (HER2)-positive breast cancers treated with HER2 targeted therapy. Journal Of Clinical Oncology 2017, 35: 1021-1021. DOI: 10.1200/jco.2017.35.15_suppl.1021.
- 40P Immune pruning of genomic heterogeneity in TNBCKarn T, Jiang T, Hatzis C, Sänger N, El-Balat A, Rody A, Holtrich U, Becker S, Bianchini G, Pusztai L. 40P Immune pruning of genomic heterogeneity in TNBC. Annals Of Oncology 2017, 28: i15. DOI: 10.1093/annonc/mdx140.002.
- Health economic impact of breast cancer index (BCI) in patients with hormone responsive breast cancer (HRBC) considering extended adjuvant endocrine therapy (EET).Sanft T, Berkowitz A, Schroeder B, Hatzis C, Schnabel C, Aktas B, Brufsky A, Pusztai L, Gustavsen G, Van Londen G. Health economic impact of breast cancer index (BCI) in patients with hormone responsive breast cancer (HRBC) considering extended adjuvant endocrine therapy (EET). Journal Of Clinical Oncology 2017, 35: 25-25. DOI: 10.1200/jco.2017.35.8_suppl.25.
- Abstract P2-09-15: A multi-institutional, prospective study of incorporating the genomic platform breast cancer index as a tool for decision-making regarding extension of adjuvant endocrine therapySanft T, Berkowitz A, Schroeder B, Hatzis C, Schnabel C, Aktas B, Brufsky A, Pusztai L, vanLonden G. Abstract P2-09-15: A multi-institutional, prospective study of incorporating the genomic platform breast cancer index as a tool for decision-making regarding extension of adjuvant endocrine therapy. Cancer Research 2017, 77: p2-09-15-p2-09-15. DOI: 10.1158/1538-7445.sabcs16-p2-09-15.
- Abstract P6-09-23: SETER/PR - A robust 18-gene predictor of sensitivity to endocrine therapy in metastatic breast cancerSinn B, Tsai T, Lau R, Fu C, Gould R, Murthy R, King T, Hatzis C, Kwiatkowski D, Valero V, Symmans W. Abstract P6-09-23: SETER/PR - A robust 18-gene predictor of sensitivity to endocrine therapy in metastatic breast cancer. Cancer Research 2017, 77: p6-09-23-p6-09-23. DOI: 10.1158/1538-7445.sabcs16-p6-09-23.
- Abstract P6-09-49: Three-gene signature predictive of high residual risk of recurrence after adjuvant chemotherapy in ER-positive HER2-negative breast cancerGyörffy B, Ocana A, Herman P, Hatzis C, Pandiella A, Pusztai L. Abstract P6-09-49: Three-gene signature predictive of high residual risk of recurrence after adjuvant chemotherapy in ER-positive HER2-negative breast cancer. Cancer Research 2017, 77: p6-09-49-p6-09-49. DOI: 10.1158/1538-7445.sabcs16-p6-09-49.
- Abstract S1-07: Immune sculpting of the triple negative breast cancer genomeKarn T, Jiang T, Hatzis C, Sänger N, El-Balat A, Holtrich U, Becker S, Bianchini G, Pusztai L. Abstract S1-07: Immune sculpting of the triple negative breast cancer genome. Cancer Research 2017, 77: s1-07-s1-07. DOI: 10.1158/1538-7445.sabcs16-s1-07.
- Genomic Markers in ER-Negative Breast CancerKarn T, Hatzis C. Genomic Markers in ER-Negative Breast Cancer. 2016, 283-298. DOI: 10.1007/978-3-319-41761-5_19.
- Revisiting inconsistency in large pharmacogenomic studiesSafikhani Z, Smirnov P, Freeman M, El-Hachem N, She A, Rene Q, Goldenberg A, Birkbak N, Hatzis C, Shi L, Beck A, Aerts H, Quackenbush J, Haibe-Kains B. Revisiting inconsistency in large pharmacogenomic studies. F1000Research 2016, 5: 2333. DOI: 10.12688/f1000research.9611.1.
- Association between DNA level aberrations and immune cell infiltration in breast cancer.Safonov A, Jiang T, Bianchini G, Platt J, Shi W, Rimm D, Pusztai L, Hatzis C. Association between DNA level aberrations and immune cell infiltration in breast cancer. Journal Of Clinical Oncology 2016, 34: 3078-3078. DOI: 10.1200/jco.2016.34.15_suppl.3078.
- Defekte homologe Rekombination als einheitlicher Biomarker beim MammakarzinomWahlde M, Timms K, Chagpar A, Wali V, Jiang T, Bossuyt V, Saglam O, Reid J, Gutin A, Neff C, Lanchbury J, Hatzis C, Hofstatter E, Pustzai L. Defekte homologe Rekombination als einheitlicher Biomarker beim Mammakarzinom. Senologie - Zeitschrift Für Mammadiagnostik Und -therapie 2016, 13 DOI: 10.1055/s-0036-1583463.
- Abstract P6-13-06: Novel combination therapies for triple negative breast cancer identified by high-throughput screeningWali V, Langdon C, Held M, Platt J, Safonov A, Aktas B, Stern D, Pusztai L, Hatzis C. Abstract P6-13-06: Novel combination therapies for triple negative breast cancer identified by high-throughput screening. Cancer Research 2016, 76: p6-13-06-p6-13-06. DOI: 10.1158/1538-7445.sabcs15-p6-13-06.
- Abstract P4-04-04: Triple-negative (TN) and HER2+ breast cancers (BC) have different immune milieu in primary and metastatic tumorsBianchini G, Riba M, Zambelli S, Safonov A, Ogiya R, Jiang T, Hatzis C, Niikura N, Zambetti M, Iwamoto T, Pusztai L, Gianni L. Abstract P4-04-04: Triple-negative (TN) and HER2+ breast cancers (BC) have different immune milieu in primary and metastatic tumors. Cancer Research 2016, 76: p4-04-04-p4-04-04. DOI: 10.1158/1538-7445.sabcs15-p4-04-04.
- Abstract P4-07-01: DNA repair deficiency enhances immune response and correlates with excellent clinical outcome in triple negative breast cancerJiang T, Safonov A, Bianchini G, Shi W, Wali V, Pusztai L, Hatzis C. Abstract P4-07-01: DNA repair deficiency enhances immune response and correlates with excellent clinical outcome in triple negative breast cancer. Cancer Research 2016, 76: p4-07-01-p4-07-01. DOI: 10.1158/1538-7445.sabcs15-p4-07-01.
- Abstract P5-07-09: Heterogeneity of tumor infiltrating lymphocytes in breast cancer and its impact for use as a biomarkerMani N, Schalper K, Hatzis C, Chagpar A, Pusztai L, Rimm D. Abstract P5-07-09: Heterogeneity of tumor infiltrating lymphocytes in breast cancer and its impact for use as a biomarker. Cancer Research 2016, 76: p5-07-09-p5-07-09. DOI: 10.1158/1538-7445.sabcs15-p5-07-09.
- Abstract P6-11-03: A cost effectiveness analysis of baseline left ventricular function assessment for breast cancer patients undergoing anthracycline chemotherapySafonov A, Hatzis C, Stratton J, Gross C, Russell R, Pusztai L, Abu-Khalaf M. Abstract P6-11-03: A cost effectiveness analysis of baseline left ventricular function assessment for breast cancer patients undergoing anthracycline chemotherapy. Cancer Research 2016, 76: p6-11-03-p6-11-03. DOI: 10.1158/1538-7445.sabcs15-p6-11-03.
- Abstract S5-01: Whole exome sequencing of pre-treatment biopsies from the neoALTTO trial to identify DNA aberrations associated with response to HER2-targeted therapiesPusztai L, Shi W, Jiang T, Nuciforo P, Holmes E, Harbeck N, Sotiriou C, Rimm D, Hatzis C, de la Peña L, Armour A, Piccart-Gebhart M, Baselga J. Abstract S5-01: Whole exome sequencing of pre-treatment biopsies from the neoALTTO trial to identify DNA aberrations associated with response to HER2-targeted therapies. Cancer Research 2016, 76: s5-01-s5-01. DOI: 10.1158/1538-7445.sabcs15-s5-01.
- Abstract A32: MCL1 gene amplification in breast cancer is associated with TNBC status and can respond to a sorafenib/vorinostat regimenRoss J, Wang K, Johnson A, Watson J, Hatzis C, Pusztai L, Chmielecki J, Yelensky R, Lipson D, Elvin J, Vergilio J, Suh J, Miller V, Dicke K, Stephens P, Ali S. Abstract A32: MCL1 gene amplification in breast cancer is associated with TNBC status and can respond to a sorafenib/vorinostat regimen. Molecular Cancer Research 2016, 14: a32-a32. DOI: 10.1158/1557-3125.advbc15-a32.
- Chapter 9 Pharmacological and Genetic Screening of Molecularly Characterized Cell LinesSafikhani Z, Selby H, Sayad A, Hatzis C, Haibe-Kains B. Chapter 9 Pharmacological and Genetic Screening of Molecularly Characterized Cell Lines. 2016, 181-213. DOI: 10.1039/9781782626770-00181.
- Characterization of DNA variants in the human kinome in breast cancerAgarwal D, Qi Y, Jiang T, Liu X, Shi W, Wali VB, Turk B, Ross JS, Fraser Symmans W, Pusztai L, Hatzis C. Characterization of DNA variants in the human kinome in breast cancer. Scientific Reports 2015, 5: 14736. PMID: 26420498, PMCID: PMC4588561, DOI: 10.1038/srep14736.
- Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy.Sanft T, Aktas B, Schroeder B, Bossuyt V, DiGiovanna M, Abu-Khalaf M, Chung G, Silber A, Hofstatter E, Mougalian S, Epstein L, Hatzis C, Schnabel C, Pusztai L. Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy. Journal Of Clinical Oncology 2015, 33: 538-538. DOI: 10.1200/jco.2015.33.15_suppl.538.
- Mutation-based treatment recommendations from next generation sequencing data: A comparison of web tools.Patel J, Reiner E, Bossuyt V, Epstein L, Platt J, DiGiovanna M, Chung G, Silber A, Sanft T, Hofstatter E, Mougalian S, Abu-Khalaf M, Gershkovich P, Hatzis C, Pusztai L. Mutation-based treatment recommendations from next generation sequencing data: A comparison of web tools. Journal Of Clinical Oncology 2015, 33: e12564-e12564. DOI: 10.1200/jco.2015.33.15_suppl.e12564.
- A framework to assess the cost effectiveness of predictive biomarkers in oncology: Test Incremental Cost Effectiveness Ratio (TICER).Safonov A, Shi W, Platt J, Aktas B, Kurita T, Pusztai L, Hatzis C. A framework to assess the cost effectiveness of predictive biomarkers in oncology: Test Incremental Cost Effectiveness Ratio (TICER). Journal Of Clinical Oncology 2015, 33: 6621-6621. DOI: 10.1200/jco.2015.33.15_suppl.6621.
- Abstract PD3-2: Broad exonic DNA diversity is associated with resistance to taxane-FAC chemotherapy in triple negative breast cancerJiang T, Shi W, Symmans W, Li C, Platt J, Lau R, Wali V, Lifton R, Pusztai L, Hatzis C. Abstract PD3-2: Broad exonic DNA diversity is associated with resistance to taxane-FAC chemotherapy in triple negative breast cancer. 2015, pd3-2-pd3-2. DOI: 10.1158/1538-7445.sabcs14-pd3-2.
- Abstract P2-03-05: The heterogeneous clinical behavior of luminal breast cancers is associated with different mutational landscapesBianchini G, Galeota E, Jiang T, Callari M, Zambetti M, Iwamoto T, Karn T, Hatzis C, Pusztai L, Gianni L. Abstract P2-03-05: The heterogeneous clinical behavior of luminal breast cancers is associated with different mutational landscapes. 2015, p2-03-05-p2-03-05. DOI: 10.1158/1538-7445.sabcs14-p2-03-05.
- Abstract P2-05-04: Gene expression associated with poor prognosis of young TNBC patientsKarn T, Pusztai L, Liedtke C, Bianchini G, Györffy B, Hatzis C, Rody A, Müller V, Schmidt M, Holtrich U, Becker S. Abstract P2-05-04: Gene expression associated with poor prognosis of young TNBC patients. 2015, p2-05-04-p2-05-04. DOI: 10.1158/1538-7445.sabcs14-p2-05-04.
- Abstract PD3-4: Reliability of whole exome sequencing for assessing intratumor heterogeneity from breast tumor biopsiesShi W, Chagpar A, Jiang T, Lannin D, Killelea B, Horowitz N, Lim R, Platt J, Ng C, Wali V, Weigelt B, Reis-Filho J, Hatzis C, Pusztai L. Abstract PD3-4: Reliability of whole exome sequencing for assessing intratumor heterogeneity from breast tumor biopsies. 2015, pd3-4-pd3-4. DOI: 10.1158/1538-7445.sabcs14-pd3-4.
- Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancersKhan SS, Karn T, Symmans WF, Rody A, Müller V, Holtrich U, Becker S, Pusztai L, Hatzis C. Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers. Breast Cancer Research And Treatment 2015, 149: 789-797. PMID: 25651779, DOI: 10.1007/s10549-015-3277-7.
- Statistical measures of transcriptional diversity capture genomic heterogeneity of cancerJiang T, Shi W, Natowicz R, Ononye SN, Wali VB, Kluger Y, Pusztai L, Hatzis C. Statistical measures of transcriptional diversity capture genomic heterogeneity of cancer. BMC Genomics 2014, 15: 876. PMID: 25294321, PMCID: PMC4197225, DOI: 10.1186/1471-2164-15-876.
- Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?Hatzis C, Bedard PL, Birkbak NJ, Beck AH, Aerts HJ, Stern D, Shi L, Clarke R, Quackenbush J, Haibe-Kains B. Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward? Cancer Research 2014, 74: 4016-4023. PMID: 25015668, PMCID: PMC4119520, DOI: 10.1158/0008-5472.can-14-0725.
- Cardiac outcomes in women receiving aromatase inhibitors as adjuvant endocrine therapy for breast cancer.Park E, Abu-Khalaf M, Hatzis C, LaSala J, Silber A, Hofstatter E, Sanft T, Russell R. Cardiac outcomes in women receiving aromatase inhibitors as adjuvant endocrine therapy for breast cancer. Journal Of Clinical Oncology 2014, 32: e11501-e11501. DOI: 10.1200/jco.2014.32.15_suppl.e11501.
- Common Contaminants in Next-Generation Sequencing That Hinder Discovery of Low-Abundance MicrobesLaurence M, Hatzis C, Brash DE. Common Contaminants in Next-Generation Sequencing That Hinder Discovery of Low-Abundance Microbes. PLOS ONE 2014, 9: e97876. PMID: 24837716, PMCID: PMC4023998, DOI: 10.1371/journal.pone.0097876.
- Bioinformatics analysis pipeline for exome sequencing dataHatzis C. Bioinformatics analysis pipeline for exome sequencing data. AACR Education Book 2014, 2014: 131. DOI: 10.1158/aacr.edb-14-6406.
- Abstract P4-06-05: Transcriptional heterogeneity correlates with chemotherapy sensitivity in triple negative breast cancer and varies by molecular subtypeJiang T, Shi W, Ononye S, Han G, Wali V, Pusztai L, Hatzis C. Abstract P4-06-05: Transcriptional heterogeneity correlates with chemotherapy sensitivity in triple negative breast cancer and varies by molecular subtype. Cancer Research 2013, 73: p4-06-05-p4-06-05. DOI: 10.1158/0008-5472.sabcs13-p4-06-05.
- Abstract P6-06-09: Baseline assessment of left ventricular function for breast cancer patients undergoing anthracycline and/or trastuzumab: What is the prevalence of baseline dysfunction?Abu-Khalaf M, Medic I, Hatzis C, Park E, Chung G, DiGiovanna M, Hofstatter E, Sanft T, Pusztai L, Gross C, Russell K, Russell R. Abstract P6-06-09: Baseline assessment of left ventricular function for breast cancer patients undergoing anthracycline and/or trastuzumab: What is the prevalence of baseline dysfunction? Cancer Research 2013, 73: p6-06-09-p6-06-09. DOI: 10.1158/0008-5472.sabcs13-p6-06-09.
- Abstract P6-06-37: Predicting improvements in survival based on improvements in pathologic response rate to neoadjuvant chemotherapy in different breast cancer subtypesHatzis C, Gould R, Zhang Y, Abu-Khalaf M, Chung G, Sanft T, Hofstatter E, DiGiovanna M, Shi W, Chagpar A, Symmans W, Pusztai L. Abstract P6-06-37: Predicting improvements in survival based on improvements in pathologic response rate to neoadjuvant chemotherapy in different breast cancer subtypes. Cancer Research 2013, 73: p6-06-37-p6-06-37. DOI: 10.1158/0008-5472.sabcs13-p6-06-37.
- Abstract P6-11-03: Follow up of breast cancer patients who underwent gamma knife radiosurgery for a diagnosis of brain metastases: A single institutional experienceAbu-Khalaf M, Hatzis C, Chung G, DiGiovanna M, Tara S, Erin H, Lajos P, James Y, Veronica C. Abstract P6-11-03: Follow up of breast cancer patients who underwent gamma knife radiosurgery for a diagnosis of brain metastases: A single institutional experience. Cancer Research 2013, 73: p6-11-03-p6-11-03. DOI: 10.1158/0008-5472.sabcs13-p6-11-03.
- Abstract S6-02: Long-term prognostic value of residual cancer burden (RCB) classification following neoadjuvant chemotherapySymmans W, Wei C, Gould R, Zhang Y, Hunt K, Buchholz T, Valero V, Hortobagyi G, Pusztai L, Hatzis C. Abstract S6-02: Long-term prognostic value of residual cancer burden (RCB) classification following neoadjuvant chemotherapy. Cancer Research 2013, 73: s6-02-s6-02. DOI: 10.1158/0008-5472.sabcs13-s6-02.
- 40O_PR Contribution of Analytical, Pre-Analytical and Intra-Tumoral Heterogeneity to Variance in Gene Expression Measurements from Human Breast CancersLau R, Sun H, Gould R, Hatzis C, Symmans W. 40O_PR Contribution of Analytical, Pre-Analytical and Intra-Tumoral Heterogeneity to Variance in Gene Expression Measurements from Human Breast Cancers. Annals Of Oncology 2013, 24: iii25. DOI: 10.1093/annonc/mdt083.1.
- Abstract P2-10-17: SET index predicts response to endocrine therapy rather than prognosis independently of other genomic signatures in a blinded validation study.Karn T, Hatzis C, Symmans F, Pusztai L, Ruckhäberle E, Schmidt M, Müller V, Hanker L, Heinrich T, Holtrich U, Kaufmann M, Rody A. Abstract P2-10-17: SET index predicts response to endocrine therapy rather than prognosis independently of other genomic signatures in a blinded validation study. Cancer Research 2012, 72: p2-10-17-p2-10-17. DOI: 10.1158/0008-5472.sabcs12-p2-10-17.
- Progression of genomic signatures in local and metastatic estrogen receptor-positive (ER+) breast cancer: Relevance to palliative treatment.Symmans W, Andreopoulou E, Booser D, Hatzis C, Wallace M, Zhang Y, Gong Y, Ignatiadis M, Sotiriou C, Andre F, Peintinger F, Regitnig P, Marth C, Desmedt C, Loi S, Moulder S, Hortobagyi G, Pusztai L, Valero V. Progression of genomic signatures in local and metastatic estrogen receptor-positive (ER+) breast cancer: Relevance to palliative treatment. Journal Of Clinical Oncology 2012, 30: 515-515. DOI: 10.1200/jco.2012.30.15_suppl.515.
- 12O_PR Independent Blinded Validation of the Genomic Index of Sensitivity to Endocrine Therapy (Set)Karn T, Hatzis C, Symmans W, Pusztai L, Ruckhäberle E, Schmidt M, Müller V, Holtrich U, Rody A, Kaufmann M. 12O_PR Independent Blinded Validation of the Genomic Index of Sensitivity to Endocrine Therapy (Set). Annals Of Oncology 2012, 23: ii18. DOI: 10.1016/s0923-7534(19)65684-x.
- P1-07-09: Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1%-10% ER-Positive by Immunohistochemistry.Iwamoto T, Booser D, Valero V, Murray J, Koenig K, Esteva F, Ueno N, Zhang J, Shi W, Qi Y, Matsuoka J, Hortobagyi G, Hatzis C, Symmans W, Pusztai L. P1-07-09: Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1%-10% ER-Positive by Immunohistochemistry. Cancer Research 2011, 71: p1-07-09-p1-07-09. DOI: 10.1158/0008-5472.sabcs11-p1-07-09.
- Effects of Tissue Handling on RNA Integrity and Microarray Measurements From Resected Breast CancersHatzis C, Sun H, Yao H, Hubbard RE, Meric-Bernstam F, Babiera GV, Wu Y, Pusztai L, Symmans WF. Effects of Tissue Handling on RNA Integrity and Microarray Measurements From Resected Breast Cancers. Journal Of The National Cancer Institute 2011, 103: 1871-1883. PMID: 22034635, PMCID: PMC3243675, DOI: 10.1093/jnci/djr438.
- Genomic Predictor of Survival After Chemotherapy for Breast Cancer—ReplySymmans W, Hatzis C. Genomic Predictor of Survival After Chemotherapy for Breast Cancer—Reply. JAMA 2011, 306: 707-709. DOI: 10.1001/jama.2011.1149.
- Blinded validation study of genomic predictions for survival following adjuvant sequential anthracycline-docetaxel chemotherapy with or without endocrine therapy.Symmans W, Andre F, Liu M, Delacruz J, Peintinger F, Borstnar S, Wang H, Regitnig P, Ota M, Seevaratnam S, Delaloge S, Hatzis C. Blinded validation study of genomic predictions for survival following adjuvant sequential anthracycline-docetaxel chemotherapy with or without endocrine therapy. Journal Of Clinical Oncology 2011, 29: 1030-1030. DOI: 10.1200/jco.2011.29.15_suppl.1030.
- A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast CancerHatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O’Shaughnessy J, Hortobagyi GN, Symmans WF. A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer. JAMA 2011, 305: 1873-1881. PMID: 21558518, PMCID: PMC5638042, DOI: 10.1001/jama.2011.593.
- Abstract PD07-03: A Genomic Predictor of Survival Following Taxane-Anthracycline Chemotherapy for Breast CancerSymmans W, Hatzis C, Valero V, Booser D, Esserman L, Martin M, Vidaurre T, Holmes F, Souchon E, Lluch A, Cotrina J, Gomez H, Hubbard R, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno N, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi G, Pusztai L. M. Abstract PD07-03: A Genomic Predictor of Survival Following Taxane-Anthracycline Chemotherapy for Breast Cancer. Cancer Research 2010, 70: pd07-03-pd07-03. DOI: 10.1158/0008-5472.sabcs10-pd07-03.
- Genomic Index of Sensitivity to Endocrine Therapy for Breast CancerSymmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P, Daxenbichler G, Desmedt C, Domont J, Marth C, Delaloge S, Bauernhofer T, Valero V, Booser DJ, Hortobagyi GN, Pusztai L. Genomic Index of Sensitivity to Endocrine Therapy for Breast Cancer. Journal Of Clinical Oncology 2010, 28: 4111-4119. PMID: 20697068, PMCID: PMC2953969, DOI: 10.1200/jco.2010.28.4273.
- The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models.Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ, Su Z, Chu TM, Goodsaid FM, Pusztai L, Shaughnessy JD, Oberthuer A, Thomas RS, Paules RS, Fielden M, Barlogie B, Chen W, Du P, Fischer M, Furlanello C, Gallas BD, Ge X, Megherbi DB, Symmans WF, Wang MD, Zhang J, Bitter H, Brors B, Bushel PR, Bylesjo M, Chen M, Cheng J, Cheng J, Chou J, Davison TS, Delorenzi M, Deng Y, Devanarayan V, Dix DJ, Dopazo J, Dorff KC, Elloumi F, Fan J, Fan S, Fan X, Fang H, Gonzaludo N, Hess KR, Hong H, Huan J, Irizarry RA, Judson R, Juraeva D, Lababidi S, Lambert CG, Li L, Li Y, Li Z, Lin SM, Liu G, Lobenhofer EK, Luo J, Luo W, McCall MN, Nikolsky Y, Pennello GA, Perkins RG, Philip R, Popovici V, Price ND, Qian F, Scherer A, Shi T, Shi W, Sung J, Thierry-Mieg D, Thierry-Mieg J, Thodima V, Trygg J, Vishnuvajjala L, Wang SJ, Wu J, Wu Y, Xie Q, Yousef WA, Zhang L, Zhang X, Zhong S, Zhou Y, Zhu S, Arasappan D, Bao W, Lucas AB, Berthold F, Brennan RJ, Buness A, Catalano JG, Chang C, Chen R, Cheng Y, Cui J, Czika W, Demichelis F, Deng X, Dosymbekov D, Eils R, Feng Y, Fostel J, Fulmer-Smentek S, Fuscoe JC, Gatto L, Ge W, Goldstein DR, Guo L, Halbert DN, Han J, Harris SC, Hatzis C, Herman D, Huang J, Jensen RV, Jiang R, Johnson CD, Jurman G, Kahlert Y, Khuder SA, Kohl M, Li J, Li L, Li M, Li QZ, Li S, Li Z, Liu J, Liu Y, Liu Z, Meng L, Madera M, Martinez-Murillo F, Medina I, Meehan J, Miclaus K, Moffitt RA, Montaner D, Mukherjee P, Mulligan GJ, Neville P, Nikolskaya T, Ning B, Page GP, Parker J, Parry RM, Peng X, Peterson RL, Phan JH, Quanz B, Ren Y, Riccadonna S, Roter AH, Samuelson FW, Schumacher MM, Shambaugh JD, Shi Q, Shippy R, Si S, Smalter A, Sotiriou C, Soukup M, Staedtler F, Steiner G, Stokes TH, Sun Q, Tan PY, Tang R, Tezak Z, Thorn B, Tsyganova M, Turpaz Y, Vega SC, Visintainer R, von Frese J, Wang C, Wang E, Wang J, Wang W, Westermann F, Willey JC, Woods M, Wu S, Xiao N, Xu J, Xu L, Yang L, Zeng X, Zhang J, Zhang L, Zhang M, Zhao C, Puri RK, Scherf U, Tong W, Wolfinger RD. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nature Biotechnology 2010, 28: 827-38. PMID: 20676074, PMCID: PMC3315840, DOI: 10.1038/nbt.1665.
- The Molecular Anatomy of Breast Cancer Stroma; Independent Prognostic Role in ER-Positive and ER-Negative Cancers.Bianchini G, Bianchini G, Alvarez R, Qi Y, Hatzis C, Iwamoto T, Shiang C, Coutant C, Hortobagyi G, Symmans W, Pusztai L. The Molecular Anatomy of Breast Cancer Stroma; Independent Prognostic Role in ER-Positive and ER-Negative Cancers. Cancer Research 2009, 69: 105-105. DOI: 10.1158/0008-5472.sabcs-09-105.
- From the Lab to the Clinic: Gene-Expression Profiles That Are Associated with Mek-Inhibitor Sensitivity In Vitro Are Coordinately Co-Expressed in Breast Cancer Biopsy Samples from the I-SPY Trial (CALGB 150007/150012, ACRIN 6657).Wolf D, Das D, Lenburg M, Paquette J, Spellman P, Gray J, Gray J, Pusztai L, Symmans F, Hatzis C, Esserman L, van 't Veer L, I-SPY Investigators .. From the Lab to the Clinic: Gene-Expression Profiles That Are Associated with Mek-Inhibitor Sensitivity In Vitro Are Coordinately Co-Expressed in Breast Cancer Biopsy Samples from the I-SPY Trial (CALGB 150007/150012, ACRIN 6657). Cancer Research 2009, 69: 2042-2042. DOI: 10.1158/0008-5472.sabcs-09-2042.
- Correlations of estrogen receptor (ER) related genomic transcription and ER gene expression with increasing AJCC stage of ER-positive breast cancerAndreopoulou E, Hatzis C, Booser D, Valero V, Wallace M, Sotiriou C, Hortobagyi G, Pusztai L, Symmans W. Correlations of estrogen receptor (ER) related genomic transcription and ER gene expression with increasing AJCC stage of ER-positive breast cancer. Journal Of Clinical Oncology 2009, 27: 1044-1044. DOI: 10.1200/jco.2009.27.15_suppl.1044.
- Commercialized Multigene Predictors of Clinical Outcome for Breast CancerRoss J, Hatzis C, Symmans W, Pusztai L, Hortobágyi G. Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer. The Oncologist 2008, 13: 921-921. DOI: 10.1634/theoncologist.2007-0248erratum.
- Prognostic value of residual cancer burden after neoadjuvant taxane-anthracycline chemotherapy in phenotypic subsets of breast cancerHubbard R, Peintinger F, Liedtke C, Hatzis C, Kuerer H, Valero V, Buzdar A, Hortobagyi G, Pusztai L, Symmans W. Prognostic value of residual cancer burden after neoadjuvant taxane-anthracycline chemotherapy in phenotypic subsets of breast cancer. Journal Of Clinical Oncology 2008, 26: 544-544. DOI: 10.1200/jco.2008.26.15_suppl.544.
- Use of genomic grade index (GGI) to predict pathologic response to preoperative chemotherapy in breast cancerSymmans W, Hatzis C, Liedtke C, Desmedt C, Valero V, Kuerer H, Hortobagyi G, Piccart- Gebhart M, Pusztai L, Sotiriou C. Use of genomic grade index (GGI) to predict pathologic response to preoperative chemotherapy in breast cancer. Journal Of Clinical Oncology 2008, 26: 541-541. DOI: 10.1200/jco.2008.26.15_suppl.541.
- Combined use of genomic prognostic and treatment response predictors in breast cancerPusztai L, Hatzis C, Cardoso F, Sotiriou C, Lazar V, Piccart-Gebhart M, Hortobagyi G, van't Veer L, Symmans W. Combined use of genomic prognostic and treatment response predictors in breast cancer. Journal Of Clinical Oncology 2008, 26: 527-527. DOI: 10.1200/jco.2008.26.15_suppl.527.
- Genomic predictors of pathologic response to preoperative chemotherapy for triple-negative and ER-positive/HER2-negative breast cancersHatzis C, Symmans W, Lin F, Zheng B, Yan K, Booser D, Gong Y, Valero V, Hortobagyi G, Pusztai L. Genomic predictors of pathologic response to preoperative chemotherapy for triple-negative and ER-positive/HER2-negative breast cancers. Journal Of Clinical Oncology 2008, 26: 571-571. DOI: 10.1200/jco.2008.26.15_suppl.571.
- Inter-pathologist agreement of residual cancer burden (rcb) assessment in breast cancer after treatment with preoperative chemotherapyPeintinger F, Hatzis C, Morkowski J, Hubbard R, Albarracin C, Qureshi G, Pusztai L, Symmans W. Inter-pathologist agreement of residual cancer burden (rcb) assessment in breast cancer after treatment with preoperative chemotherapy. Journal Of Clinical Oncology 2008, 26: 576-576. DOI: 10.1200/jco.2008.26.15_suppl.576.
- Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant ChemotherapySymmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L. Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy. Journal Of Clinical Oncology 2007, 25: 4414-4422. PMID: 17785706, DOI: 10.1200/jco.2007.10.6823.
- The impact of hormone receptor status on pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy with or without trastuzumabPeintinger F, Buzdar A, Kuerer H, Gonzalez-Angulo A, Hatzis C, Pusztai L, Esteva F, Green M, Hortobagyi G, Symmans W. The impact of hormone receptor status on pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy with or without trastuzumab. Journal Of Clinical Oncology 2007, 25: 533-533. DOI: 10.1200/jco.2007.25.18_suppl.533.
- Large-scale identification of novel transcripts in the human genomePeters BA, St. Croix B, Sjöblom T, Cummins JM, Silliman N, Ptak J, Saha S, Kinzler KW, Hatzis C, Velculescu VE. Large-scale identification of novel transcripts in the human genome. Genome Research 2007, 17: 287-292. PMID: 17267814, PMCID: PMC1800919, DOI: 10.1101/gr.5486607.
- A new measurement of residual cancer burden to predict survival after neoadjuvant chemotherapySymmans W, Peintinger F, Hatzis C, Kuerer H, Valero V, Hennessy B, Green M, Singletary E, Hortobagyi G, Pusztai L. A new measurement of residual cancer burden to predict survival after neoadjuvant chemotherapy. Journal Of Clinical Oncology 2006, 24: 536-536. DOI: 10.1200/jco.2006.24.18_suppl.536.
- Ambient Particulate Matter Exhibits Direct Inhibitory Effects on Oxidative Stress EnzymesHatzis C, Godleski J, González-Flecha B, Wolfson J, Koutrakis P. Ambient Particulate Matter Exhibits Direct Inhibitory Effects on Oxidative Stress Enzymes. Environmental Science And Technology 2006, 40: 2805-2811. PMID: 16683627, DOI: 10.1021/es0518732.
- KDD Cup 2001 reportCheng J, Hatzis C, Hayashi H, Krogel M, Morishita S, Page D, Sese J. KDD Cup 2001 report. ACM SIGKDD Explorations Newsletter 2002, 3: 47-64. DOI: 10.1145/507515.507523.
- Toxicity of hardwood extractives toward Saccharomyces cerevisiae glucose fermentationRanatunga T, Jervis J, Helm R, McMillan J, Hatzis C. Toxicity of hardwood extractives toward Saccharomyces cerevisiae glucose fermentation. Biotechnology Letters 1997, 19: 1125-1127. DOI: 10.1023/a:1018400912828.
- Identification of inhibitory components toxic toward zymomonas mobilis CP4(pZB5) xylose fermentationRanatunga T, Jervis J, Helm R, McMillan J, Hatzis C. Identification of inhibitory components toxic toward zymomonas mobilis CP4(pZB5) xylose fermentation. Applied Biochemistry And Biotechnology 1997, 67: 185. DOI: 10.1007/bf02788797.
- Biochemical Engineering Analysis of Critical Process Factors in the Biomass‐to‐Ethanol TechnologyPhilippidis G, Hatzis C. Biochemical Engineering Analysis of Critical Process Factors in the Biomass‐to‐Ethanol Technology. Biotechnology Progress 1997, 13: 222-231. PMID: 9190073, DOI: 10.1021/bp970017u.
- Cell-Cycle Analysis in Phagotrophic Microorganisms from Flow Cytometric HistogramsHatzis C, Frederickson A, Srienc F. Cell-Cycle Analysis in Phagotrophic Microorganisms from Flow Cytometric Histograms. Journal Of Theoretical Biology 1997, 186: 131-144. DOI: 10.1006/jtbi.1996.0348.
- Session 3 bioprocessing researchDorsch R, Hatzis C. Session 3 bioprocessing research. Applied Biochemistry And Biotechnology 1997, 63-65: 349-349. DOI: 10.1007/bf02920436.
- Bioprocessing ResearchDorsch R, Hatzis C. Bioprocessing Research. 1997, 63-65: 349-349. PMID: 18576093, DOI: 10.1007/978-1-4612-2312-2_30.
- Development of an epi-fluorescence assay for monitoring yeast viability and pretreatment hydrolysate toxicity in the presence of lignocellulosic solidsCombs N, Hatzis C. Development of an epi-fluorescence assay for monitoring yeast viability and pretreatment hydrolysate toxicity in the presence of lignocellulosic solids. Applied Biochemistry And Biotechnology 1996, 57-58: 649. PMID: 8669916, DOI: 10.1007/bf02941746.
- Detailed material balance and ethanol yield calculations for the biomass-to-ethanol conversion processHatzis C, Riley C, Philippidis G. Detailed material balance and ethanol yield calculations for the biomass-to-ethanol conversion process. Applied Biochemistry And Biotechnology 1996, 57-58: 443. DOI: 10.1007/bf02941725.
- Measurement of the inhibitory potential and detoxification of biomass pretreatment hydrolysate for ethanol productionRivard C, Engel R, Hayward T, Nagle N, Hatzis C, Philippidis G. Measurement of the inhibitory potential and detoxification of biomass pretreatment hydrolysate for ethanol production. Applied Biochemistry And Biotechnology 1996, 57-58: 183. DOI: 10.1007/bf02941698.
- Optimization of reverse-flow, two-temperature, dilute-acid pretreatment to enhance biomass conversion to ethanolTorget R, Hatzis C, Hayward T, Hsu T, Philippidis G. Optimization of reverse-flow, two-temperature, dilute-acid pretreatment to enhance biomass conversion to ethanol. Applied Biochemistry And Biotechnology 1996, 57-58: 85. DOI: 10.1007/bf02941691.
- Measurement of the Inhibitory Potential and Detoxification of Biomass Pretreatment Hydrolysate for Ethanol ProductionRivard C, Engel R, Hayward T, Nagle N, Hatzis C, Philippidis G. Measurement of the Inhibitory Potential and Detoxification of Biomass Pretreatment Hydrolysate for Ethanol Production. 1996, 183-191. DOI: 10.1007/978-1-4612-0223-3_16.
- Detailed Material Balance and Ethanol Yield Calculations for the Biomass-to-Ethanol Conversion ProcessHatzis C, Riley C, Philippidis G. Detailed Material Balance and Ethanol Yield Calculations for the Biomass-to-Ethanol Conversion Process. 1996, 443-459. DOI: 10.1007/978-1-4612-0223-3_41.
- Development of an Epi-Fluorescence Assay for Monitoring Yeast Viability and Pretreatment Hydrolysate Toxicity in the Presence of Lignocellulosic SolidsCombs N, Hatzis C. Development of an Epi-Fluorescence Assay for Monitoring Yeast Viability and Pretreatment Hydrolysate Toxicity in the Presence of Lignocellulosic Solids. 1996, 649-657. DOI: 10.1007/978-1-4612-0223-3_62.
- Optimization of Reverse-Flow, Two-Temperature, Dilute-Acid Pretreatment to Enhance Biomass Conversion to EthanolTorget R, Hatzis C, Hayward T, Hsu T, Philippidis G. Optimization of Reverse-Flow, Two-Temperature, Dilute-Acid Pretreatment to Enhance Biomass Conversion to Ethanol. 1996, 85-101. DOI: 10.1007/978-1-4612-0223-3_9.
- Multistaged corpuscular models of microbial growth: Monte Carlo simulationsHatzis C, Srienc F, Fredrickson A. Multistaged corpuscular models of microbial growth: Monte Carlo simulations. Biosystems 1995, 36: 19-35. PMID: 8527693, DOI: 10.1016/0303-2647(95)01524-o.
- Feeding heterogeneity in ciliate populations: Effects of culture age and nutritional stateHatzis C, Srienc F, Fredrickson A. Feeding heterogeneity in ciliate populations: Effects of culture age and nutritional state. Biotechnology And Bioengineering 1994, 43: 371-380. PMID: 18615720, DOI: 10.1002/bit.260430505.
- Determination of cellular rate distributions in microbial cell populations: Feeding rates of ciliated protozoaHatzis C, Sweeney P, Srienc F, Fredrickson A. Determination of cellular rate distributions in microbial cell populations: Feeding rates of ciliated protozoa. Biotechnology And Bioengineering 1993, 42: 284-294. PMID: 18613011, DOI: 10.1002/bit.260420304.
- Optimal Design in Nonlinear Multiresponse Estimation: Poisson Model for Filter FeedingHatzis C, Larntz K. Optimal Design in Nonlinear Multiresponse Estimation: Poisson Model for Filter Feeding. Biometrics 1992, 48: 1235. DOI: 10.2307/2532715.
- A statistical analysis of flow cytometric determinations of phagocytosis ratesFredrickson A, Hatzis C, Srienc F. A statistical analysis of flow cytometric determinations of phagocytosis rates. Cytometry 1992, 13: 423-431. PMID: 1526200, DOI: 10.1002/cyto.990130413.
- A discrete, stochastic model for microbial filter feeding: a model for feeding of ciliated protists on spatially uniform, nondepletable suspensionsHatzis C, Sweeney P, Srienc F, Fredrickson A. A discrete, stochastic model for microbial filter feeding: a model for feeding of ciliated protists on spatially uniform, nondepletable suspensions. Mathematical Biosciences 1990, 102: 127-181. PMID: 2134491, DOI: 10.1016/0025-5564(90)90060-c.
- Size Effects on the Uptake of Particles by Populations of Tetrahymena pyriformis CellsLAVIN D, HATZIS C, SRIENC F, FREDRICKSON A. Size Effects on the Uptake of Particles by Populations of Tetrahymena pyriformis Cells. Journal Of Eukaryotic Microbiology 1990, 37: 157-163. DOI: 10.1111/j.1550-7408.1990.tb01120.x.